Hormone-sensitive lipase is involved in the action of hydroxysafflor yellow A (HYSA) inhibiting adipogenesis of 3T3-L1cells.
BACKGROUND
Safflor yellow A (SY) has been demonstrated to be beneficial to cardiovascular system. Our previous study showed that hydroxysafflor yellow A (HSYA), a main component of SY, could increase peroxisome proliferator-activated receptor γ mRNA expression. In this study, we investigate the effect of HSYA on the proliferation and adipogenesis of mouse 3T3-L1 preadipocytes.


METHODS
The proliferation and adipogenesis of 3T3-L1 cells treated with HSYA was studied by 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyl tetrazolium bromide (MTT) spectrophotometry, Oil Red O staining and intracellular triglyceride assay methods. HSL mRNA expression and promoter activity were studied by real-time quantitative RT-PCR, transient transfection and dual luciferase reporter gene methods.


RESULTS
HSYA (0.1 mg/L) significantly inhibited the proliferation of 3T3-L1 cells when compared with control cells in 8 h. This effect was further enhanced with the extension time (24 to 96 h) and an increase of concentration of HSYA (1-10 mg/L). The maximal inhibitory action was observed at 0.1 mg/L HSYA in 72 h (86±11.8% vs. 100±4.1%, p<0.01). HSYA notably reduced the amount of intracellular lipid and triglyceride content in adipocytes to 85% (1 mg/L) and 75% (100 mg/L) on Day 4 following the differentiation, respectively, while increased HSL mRNA expression and promoter activities to 2.7 fold and 1.55 fold, respectively (p<0.01), in differentiated 3T3-L1 adipocytes.


CONCLUSIONS
HSYA inhibits the proliferation and adipogenesis of 3T3-L1 preadipocytes. The inhibitory action of HYSA on adipogenesis may be due to the promotion of lipolytic-specific enzyme HSL expression by increasing HSL promoter activity.
Department of Endocrinology, Key Laboratory of Endocrinology of Ministry of Health, The Translational Medicine Center of PUMCH, Peking Union Medical College Hospital, Beijing 100730, China; Chinese Academy of Medical Sciences, Beijing 100730, China; Peking Union Medical College, Beijing 100730, China.
Hui-juan
HJ
Zhu
Department of Endocrinology, Key Laboratory of Endocrinology of Ministry of Health, The Translational Medicine Center of PUMCH, Peking Union Medical College Hospital, Beijing 100730, China; Chinese Academy of Medical Sciences, Beijing 100730, China; Peking Union Medical College, Beijing 100730, China.
Lin-jie
LJ
Wang
Department of Endocrinology, Key Laboratory of Endocrinology of Ministry of Health, The Translational Medicine Center of PUMCH, Peking Union Medical College Hospital, Beijing 100730, China; Chinese Academy of Medical Sciences, Beijing 100730, China; Peking Union Medical College, Beijing 100730, China.
Xiang-qing
XQ
Wang
Department of Endocrinology, Key Laboratory of Endocrinology of Ministry of Health, The Translational Medicine Center of PUMCH, Peking Union Medical College Hospital, Beijing 100730, China; Chinese Academy of Medical Sciences, Beijing 100730, China; Peking Union Medical College, Beijing 100730, China.
Hui
H
Pan
Department of Endocrinology, Key Laboratory of Endocrinology of Ministry of Health, The Translational Medicine Center of PUMCH, Peking Union Medical College Hospital, Beijing 100730, China; Chinese Academy of Medical Sciences, Beijing 100730, China; Peking Union Medical College, Beijing 100730, China.
Nai-shi
NS
Li
Department of Endocrinology, Key Laboratory of Endocrinology of Ministry of Health, The Translational Medicine Center of PUMCH, Peking Union Medical College Hospital, Beijing 100730, China; Chinese Academy of Medical Sciences, Beijing 100730, China; Peking Union Medical College, Beijing 100730, China.
Hong-bo
HB
Yang
Department of Pharmacology, Beijing Anzhen Hospital, Capital Medical University, China-Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing 100029, China.
Ming
M
Jin
Department of Pharmacology, Beijing Anzhen Hospital, Capital Medical University, China-Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing 100029, China.
Bao-xia
BX
Zang
Department of Endocrinology, Key Laboratory of Endocrinology of Ministry of Health, The Translational Medicine Center of PUMCH, Peking Union Medical College Hospital, Beijing 100730, China; Chinese Academy of Medical Sciences, Beijing 100730, China; Peking Union Medical College, Beijing 100730, China. Electronic address: fygong@sina.com.
Feng-ying
FY
Gong
D041721:3T3-L1 Cells; D050156:Adipogenesis / Q000187:drug effects*; D000818:Animals; D001391:Azo Compounds; D031187:Carthamus tinctorius / Q000737:chemistry; D049109:Cell Proliferation / Q000187:drug effects*; D002599:Chalcone / Q000031:analogs & derivatives* / Q000494:pharmacology; D050356:Lipid Metabolism / Q000187:drug effects*; D051379:Mice; D011401:Promoter Regions, Genetic; D011809:Quinones / Q000494:pharmacology*; D002787:Sterol Esterase / Q000235:genetics / Q000378:metabolism*; D015533:Transcriptional Activation / Q000187:drug effects; D014280:Triglycerides / Q000032:analysis
D001391:Azo Compounds; D011809:Quinones; D014280:Triglycerides; C085278:hydroxysafflor yellow A; D002599:Chalcone; D002787:Sterol Esterase; C011049:oil red O
3T3-L1 preadipocytes; Adipogenesis; Hormone-sensitive lipase (HSL); Hydroxysafflor yellow A (HSYA); Proliferation